本文内容已经过同行评议,以优先出版方式在线发表,可作为有效引用数据。由于优先发表的内容尚未完成规范的编校流程,《中华外科杂志》不保证其数据与印刷版内容的完全一致。 【引用本文】陈凛,许鑫鑫,鲁意迅,等.食管胃结合部腺癌外科治疗的几个主要问题[J/OL].中华外科杂志,2022,60:网络预发表. 陈凛 许鑫鑫 鲁意迅 张珂诚 {解放军总医院第一医学中心普通外科医学部} 通信作者:陈凛,Email:chenlinbj@sina.com 最新流行病学数据显示,我国胃癌的发病率及死亡率均居恶性肿瘤的第3位[1],每年胃癌新发病例超过67万,死亡病例超过49万[2]。尽管近年来世界范围内胃癌的总体发病呈下降趋势,但是食管胃结合部腺癌(adenocarcinoma of esophagogastric junction,AEG)的发病率逐年攀升[3]。截至2019年,美国AEG发病率已由1973年的13.4/10万人年升至51.4/10万人年[4];日本国立癌症中心的数据显示,AEG占进展期胃癌的比例也由1962年的2.3%升至2005年的10.0%[5]。四川大学华西医院的单中心回顾性研究数据显示,1988—2012年AEG占胃及远端食管癌的比例由22.3%升至35.7%[6]。AEG因其特殊的解剖位置、独特的淋巴结引流方式及不良预后受到越来越多的重视和关注。 一、AEG的分型与分期 二、手术入路的选择 三、淋巴结清扫范围 四、手术切除范围 五、消化道重建方式 六、总结与展望 参考文献 (在框内滑动手指即可浏览) [1]ZhengR, ZhangS, ZengH, et al. Cancer incidence and mortality in China, 2016[J]. JNCC, 2022, 2(1): 1-9.DOI: 10.1016/j.jncc.2022.02.002. [2]ChenW, ZhengR, BaadePD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132. DOI: 10.3322/caac.21338. [3]ImamuraY, WatanabeM, ToihataT, et al. Recent incidence trend of surgically resected esophagogastric junction adenocarcinoma and microsatellite instability status in Japanese patients[J]. Digestion, 2019, 99(1):6-13. DOI: 10.1159/000494406. [4]DubeczA, SolymosiN, StadlhuberRJ, et al. Does the incidence of adenocarcinoma of the esophagus and gastric cardia continue to rise in the twenty-first century?-a SEER database analysis[J]. J Gastrointest Surg, 2014, 18(1):124-129.DOI: 10.1007/s11605-013-2345-8. [5]KusanoC, GotodaT, KhorCJ, et al. Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan[J]. J Gastroenterol Hepatol, 2008, 23(11):1662-1665. DOI: 10.1111/j.1440-1746.2008.05572.x. [6]LiuK, YangK, ZhangW, et al. Changes of esophagogastric junctional adenocarcinoma and gastroesophageal reflux disease among surgical patients during 1988-2012: a single-institution, high-volume experience in China[J]. Ann Surg, 2016, 263(1):88-95. DOI: 10.1097/SLA.0000000000001148. [7]SiewertJR, HölscherAH, BeckerK, et al. Kardiacarcinom: versuch einer therapeutisch relevanten Klassifikation[J]. Chirurg, 1987, 58(1):25-32. [8]Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver.4)[J]. Gastric Cancer, 2017, 20(1):1-19. DOI:10.1007/s10120-016-0622-4. [9]DolanK, MorrisAI, GosneyJR, et al. Three different subsite classification systems for carcinomas in the proximity of the GEJ, but is it all one disease?[J]. J Gastroenterol Hepatol, 2004, 19(1):24-30. DOI: 10.1111/j.1440-1746.2004.03280.x. [10]AjaniJA, BarthelJS, BentremDJ, et al. Esophageal and esophagogastric junction cancers[J]. J Natl Compr Canc Netw, 2011, 9(8):830-887. DOI: 10.6004/jnccn.2011.0072. [11]中华医学会外科学分会腹腔镜与内镜外科学组. Siewert Ⅱ型食管胃结合部腺癌腔镜手术治疗中国专家共识(2019版)[J].中国实用外科杂志, 2019, 39(11):1129- 1135. DOI:10.19538/j.cjps.issn1005-2208.2019.11.02. [12]RiceTW, IshwaranH, HofstetterWL, et al. Recommendations for pathologic staging (pTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals[J]. Dis Esophagus, 2016, 29(8):897-905. DOI: 10.1111/dote.12533. [13]de BoerAG, van LanschotJJ, van SandickJW, et al. Quality of life after transhiatal compared with extended transthoracic resection for adenocarcinoma of the esophagus[J]. J Clin Oncol, 2004, 22(20):4202-4208. DOI: 10.1200/JCO.2004.11.102. [14]OmlooJM, LagardeSM, HulscherJB, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial[J]. Ann Surg, 2007, 246(6):992-1001. DOI: 10.1097/SLA.0b013e31815c4037. [15]SasakoM, SanoT, YamamotoS, et al. Left thoracoabdominal approach versus abdominal- transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial[J]. Lancet Oncol, 2006, 7(8):644-651. DOI: 10.1016/S1470-2045(06)70766-5. [16]MarietteC, PiessenG, BriezN, et al. Oesophagogastric junction adenocarcinoma: which therapeutic approach?[J]. Lancet Oncol, 2011, 12(3):296-305. DOI: 10.1016/S1470-2045(10)70125-X. [17]WeiMT, ZhangYC, DengXB, et al. Transthoracic vs transhiatal surgery for cancer of the esophagogastric junction: a Meta-analysis[J]. World J Gastroenterol, 2014, 20(29):10183-10192. DOI: 10.3748/wjg.v20.i29.10183. [18]MineS, SanoT, HikiN, et al. Proximal margin length with transhiatal gastrectomy for Siewert type Ⅱ and Ⅲ adenocarcinomas of the oesophagogastric junction[J]. Br J Surg, 2013, 100(8):1050-1054. DOI: 10.1002/bjs.9170. [19]NiclaussN, JungMK, ChevallayM, et al. Minimal length of proximal resection margin in adenocarcinoma of the esophagogastric junction: a systematic review of the literature[J]. Updates Surg, 2019, 71(3):401-409. DOI: 10.1007/s13304-019-00665-w. [20]国际食管疾病学会中国分会(CSDE)食管胃结合部疾病跨界联盟, 中国医师协会内镜医师分会腹腔镜外科专业委员会, 中国医师协会外科医师分会上消化道外科医师专业委员会, 等. 食管胃结合部腺癌外科治疗中国专家共识(2018年版)[J]. 中华胃肠外科杂志, 2018, 21(9):961-975. DOI: 10.3760/cma.j.issn.1671-0274.2018.09.001. [21]SongQ, LiX, WuD, et al. The abdominal-transhiatal surgical approach versus the thoracoabdominal surgical approach in Siewert type Ⅱ adenocarcinoma of the esophagogastric junction: protocol for a multicenter prospective, open, parallel, and randomized controlled trial[J]. BMC Cancer, 2022, 22(1):318. DOI: 10.1186/s12885-022-09375-w. [22]YajinS, MurakamiG, TakeuchiH, et al. The normal configuration and interindividual differences in intramural lymphatic vessels of the esophagus[J]. J Thorac Cardiovasc Surg, 2009, 137(6):1406-1414. DOI: 10.1016/j.jtcvs.2008.08.069. [23]DresnerSM, LambPJ, BennettMK, et al. The pattern of metastatic lymph node dissemination from adenocarcinoma of the esophagogastric junction[J]. Surgery, 2001, 129(1):103-109. DOI: 10.1067/msy.2001.110024. [24]Rüdiger SiewertJ, FeithM, WernerM, et al. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1, 002 consecutive patients[J]. Ann Surg, 2000, 232(3):353-361. DOI:10.1097/00000658-200009000-00007. [25]YamashitaH, SetoY, SanoT, et al. Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma[J]. Gastric Cancer, 2017, 20Suppl 1:S69-S83. DOI:10.1007/s10120-016-0663-8. [26]FeithM, SteinHJ, SiewertJR. Adenocarcinoma of the esophagogastric junction: surgical therapy based on 1602 consecutive resected patients[J]. Surg Oncol Clin N Am, 2006, 15(4):751-764. DOI: 10.1016/j.soc.2006.07.015. [27]KurokawaY, HikiN, YoshikawaT, et al. Mediastinal lymph node metastasis and recurrence in adenocarcinoma of the esophagogastric junction[J]. Surgery, 2015, 157(3):551-555. DOI: 10.1016/j.surg.2014.08.099. [28]KurokawaY, TakeuchiH, DokiY, et al. Mapping of lymph node metastasis from esophagogastric junction tumors: a prospective nationwide multicenter study[J]. Ann Surg, 2021, 274(1):120-127. DOI: 10.1097/SLA.0000000000003499. [29]FujitaniK, MiyashiroI, MikataS, et al. Pattern of abdominal nodal spread and optimal abdominal lymphadenectomy for advanced Siewert type Ⅱ adenocarcinoma of the cardia: results of a multicenter study[J]. Gastric Cancer, 2013, 16(3):301-308. DOI: 10.1007/s10120-012-0183-0. [30]YoshikawaT, TakeuchiH, HasegawaS, et al. Theoretical therapeutic impact of lymph node dissection on adenocarcinoma and squamous cell carcinoma of the esophagogastric junction[J]. Gastric Cancer, 2016, 19(1):143-149. DOI: 10.1007/s10120-014-0439-y. [31]YamashitaH, KataiH, MoritaS, et al. Optimal extent of lymph node dissection for Siewert type Ⅱ esophagogastric junction carcinoma[J]. Ann Surg, 2011, 254(2):274-280. DOI: 10.1097/SLA.0b013e3182263911. [32]ChenYC, LuL, FanKH, et al. Proximal gastrectomy versus total gastrectomy for adenocarcinoma of the esophagogastric junction: a Meta-analysis[J]. J Comp Eff Res, 2019, 8(10):753-766. DOI: 10.2217/cer-2019-0016. [33]TakiguchiN, TakahashiM, IkedaM, et al. Long-term quality-of-life comparison of total gastrectomy and proximal gastrectomy by postgastrectomy syndrome assessment scale (PGSAS-45): a nationwide multi-institutional study[J]. Gastric Cancer, 2015, 18(2):407-416. DOI: 10.1007/s10120-014-0377-8. [34]HölscherAH, LawS. Esophagogastric junction adenocarcinomas: individualization of resection with special considerations for Siewert type Ⅱ, and Nishi types EG, E=G and GE cancers[J]. Gastric Cancer, 2020, 23(1):3-9. DOI: 10.1007/s10120-019-01022-x. [35]ZhangP, ZhangX, XueH. Long-term results of hand-assisted laparoscopic gastrectomy for advanced Siewert type Ⅱ and type Ⅲ esophagogastric junction adenocarcinoma[J]. Int J Surg, 2018, 53:201-205. DOI: 10.1016/j.ijsu.2018.03.004. [36]胡鹏, 梁文全, 崔建新, 等.完全腹腔镜下全胃切除术食管空肠吻合方式研究进展[J].解放军医学院学报,2022,43(4):492-496. [37]李南, 沙洪存. 全腹腔镜全胃切除食管空肠吻合的临床研究进展[J].中国微创外科杂志, 2019, 19(8):731-734. DOI: 10.3969/j.issn.1009-6604.2019.08.016. [38]FeinM, FuchsKH, ThalheimerA, et al. Long-term benefits of Roux-en-Y pouch reconstruction after total gastrectomy: a randomized trial[J]. Ann Surg, 2008, 247(5):759-765. DOI: 10.1097/SLA.0b013e318167748c. [39]NakamuraM, NakamoriM, OjimaT, et al. Reconstruction after proximal gastrectomy for early gastric cancer in the upper third of the stomach: an analysis of our 13-year experience[J]. Surgery, 2014, 156(1):57-63. DOI: 10.1016/j.surg.2014.02.015. [40]《近端胃切除消化道重建中国专家共识》编写委员会. 近端胃切除消化道重建中国专家共识(2020版)[J]. 中华胃肠外科杂志, 2020, 23(2):101-108. DOI: 10.3760/cma.j.issn.1671-0274.2020.02.002. [41]李双喜, 李子禹, 陕飞, 等. 完全腹腔镜近端胃切除双通路消化道重建术[J].中华胃肠外科杂志, 2016, 19(1):84-85. DOI: 10.3760/cma.j.issn.1671-0274.2016.01.019. [42]ChiaD, KimG, ChangH, et al. Kamikawa double-flap reconstruction after minimally invasive ivor-lewis esophagectomy[J]. Ann Thorac Surg, 2019, 108(1):e57-e59. DOI: 10.1016/j.athoracsur.2019.01.077. |
|
来自: zhaozhaozhao3 > 《胃外科》